Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation

Baigalmaa Lkhagva, Yu Hsun Kao, Yao Chang Chen, Tze Fan Chao, Shih Ann Chen, Yi Jen Chen

Research output: Contribution to journalReview articlepeer-review

17 Citations (Scopus)


Atrial fibrillation (AF) is a common cardiac arrhythmia associated with high mortality and morbidity. Current treatments of AF have limited efficacy and considerable side effects. Histone deacetylases (HDACs) play critical roles in the pathophysiology of cardiovascular diseases and contribute to the genesis of AF. Therefore, HDAC inhibition may prove a novel therapeutic strategy for AF through upstream therapy and modifications of AF electrical and structural remodeling. In this review, we provide an update of the knowledge of the effects of HDACs and HDAC inhibitors on AF, and dissect potential underlying mechanisms.

Original languageEnglish
Pages (from-to)250-257
Number of pages8
JournalEuropean Journal of Pharmacology
Publication statusPublished - 2016


  • Atrial fibrillation
  • HDAC inhibitors
  • Histone deacetylases
  • Non-histone proteins

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation'. Together they form a unique fingerprint.

Cite this